Galderma and National Breast Cancer Foundation Announce Continued Partnership to Launch Campaign Elevating Skin Stories of Breast Cancer Survivors

DALLAS, Oct. 3, 2022 /PRNewswire/ -- Galderma announced today its continued partnership with National Breast Cancer Foundation Inc. (NBCF), one of the leading breast cancer organizations in the world. Galderma is committed to elevating real people's unique skin stories in an effort to increase the understanding of treatment needs for patients of all backgrounds and experiences. Galderma is featuring the personal stories and treatment journeys of breast cancer survivors who received Galderma's Aesthetic portfolio of products, including Restylane®, Dysport®* (abobotulinumtoxinA) and/or Sculptra®, in a campaign on Galderma's social channels during Breast Cancer Awareness Month in October.

"We are proud to work with National Breast Cancer Foundation on this important and exciting project that honors breast cancer survivors," said Carrie Caulkins, Vice President, U.S. Aesthetics Marketing at Galderma. "People who have finished their treatments of chemotherapy or radiation can experience loss of facial volume, which may lower their confidence following treatment. Our collaboration with NBCF enables us to support these patients and show how they can continue to look and feel their best through the use of our leading portfolio of Aesthetic products and treatments."

This year, women from a variety of backgrounds, who have all lived with breast cancer, will be featured in video content throughout the month of October where they discuss their cancer journeys and how embracing injectables has given them the confidence to feel like themselves again.

In the month of October, Galderma will also be donating $50,000 to NBCF, bringing the total cash donation to $450,000 over the course of eight years. These funds will provide help and inspire hope to those affected by breast cancer through early detection, education, and support services.

Galderma and NBCF have had a longstanding partnership since 2015, providing ongoing financial support and contributions to a wide range of NBCF-offered programs. This includes educating and providing resources to more than 250,000 women, providing nearly 750 mammograms and diagnostic services across the U.S., supporting more than 6,500 women through patient navigation to provide help and support throughout their breast cancer journey, and contributing to the delivery of over 20,000 HOPE Kits to breast cancer patients, which include a variety of educational materials and self-care items, including Cetaphil® lotion.

"We are extremely grateful for the contributions we have received from Galderma over the past seven years that have aided our ability to empower women to take action and receive critical support to get through the many challenges of a breast cancer diagnosis," said Candice Hensley, Senior Manager of Strategic Partnerships, National Breast Cancer Foundation. "We look forward to continuing our long-standing partnership and realizing our shared mission of elevating stories to raise awareness and inspire hope."

To follow along with the breast cancer survivors' skin stories, visit www.instagram.com/gainbygalderma.usa, www.instagram.com/restylaneusa, www.instagram.com/sculptrausa, and www.instagram.com/dysportusa.

To learn more about Galderma's aesthetics portfolio, visit https://www.galderma.com/galderma-aesthetics.

For more information about NBCF, visit www.nationalbreastcancer.org/.

*Dysport is a prescription injection for temporary improvement in the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults less than 65 years of age. Please read full Important Safety Information, including Distant Spread of Toxin Effect Boxed Warning, at the bottom of the page.

Galderma is the world's largest independent dermatology company, present in approximately 100 countries. Since our inception in 1981, we have been driven by a complete dedication to dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Aesthetics, Consumer Care and Prescription Medicine. Focused on the needs of consumers and patients, we work in partnership with healthcare professionals to ensure superior outcomes. Because we understand that the skin we're in shapes our life stories, we are advancing dermatology for every skin story. For more information: www.galderma.com/us. 

Recognized as one of the leading breast cancer organizations in the world, National Breast Cancer Foundation (NBCF) is Helping Women Now® by providing early detection, education and support services to those affected by breast cancer. A recipient of Charity Navigator's highest 4-star rating for 16 years, NBCF provides support through their National Mammography Program, Patient Navigation, breast health education, and patient support programs. For more information, please visit www.nationalbreastcancer.org/ 

With over 50 million treatments worldwide¹ and counting, the Restylane® family of HA dermal fillers is a diverse and broad portfolio of dermal fillers in the U.S. These products help smooth facial wrinkles and folds, such as smile lines (Restylane® L, Restylane® Refyne, Restylane® Defyne and Restylane® Lyft with Lidocaine), augment and correct mild to moderate chin retrusion (Restylane® Defyne), create fuller and more accentuated lips (Restylane® Silk, Restylane® -L and Restylane® Kysse), add lift and volume to the cheeks and back of the hands (Restylane® Lyft with Lidocaine), and augment cheeks and correct midface contour deficiencies (Restylane® Contour). To learn more about the Restylane® family of HA dermal fillers, visit www.RestylaneUSA.com. 

Dysport® (abobotulinumtoxinA) is a prescription injection for temporary improvement in the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults less than 65 years of age. Dysport is also marketed as Azzalure® in the EU for the treatment of glabellar lines and lateral canthal lines.

Dysport has more than 30 years of clinical experience Globally for therapeutic indications and 13 years for aesthetics indications, with extensive clinical evidence of safety and efficacy. It is licensed for aesthetic indications in 85 markets worldwide, Dysport is one of the world's leading brands of aesthetic neuromodulators with over 100 million treatments delivered in the aesthetics indications to date.

Dysport® is manufactured by Ipsen, a global specialty-driven pharmaceutical company. Since 2009, Galderma and Ipsen have had a strategic partnership under which Galderma has promoted and distributed Ipsen's botulinum toxin type A products in aesthetic indications. The Ipsen-Galderma strategic partnership now covers China, the United States, Europe, the Middle East, Australia, South Korea, Canada, Brazil, Argentina, and certain other countries. Ipsen continues to promote Dysport® within certain therapeutic indications in countries around the world.

For more information on Ipsen, visit www.ipsen.com. 

Sculptra® works to help stimulate the skin's own collagen production and is indicated for use in people with healthy immune systems for the correction of shallow to deep nasolabial fold contour deficiencies and other facial wrinkles.^2,3 Sculptra is an injectable biostimulator containing microparticles of poly-l-lactic acid (PLLA) which helps gradually revitalize the skin's structural foundation, providing natural-looking, long-term results for up to 2 years**^3,4-5 Sculptra was first approved for aesthetic use in 2009 in the United States and is currently available in more than 40 countries globally. To learn more about Sculptra products, visit www.SculptraUSA.com

**Clinical study ended at 96 weeks (2 years)

Media Relations 
Zach Randles-Friedman 
Head of U.S. Communications 
[email protected] 
+1 305 299 5700 

Rachel Mooney 
Director, Global Franchise Communications 
[email protected] 
+41 58 455 85 41 /+41 76 261 64 41 

 Ashley Miller 
National Breast Cancer Foundation 
[email protected] 
+1 318 348 8855 

Dysport® (abobotulinumtoxinA) is a prescription injection for temporary improvement in the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults less than 65 years of age. 

What is the most important information you should know about Dysport? Spread of Toxin Effects: In some cases, the effects of Dysport and all botulinum toxin products may affect areas of the body away from the injection site. Symptoms can happen hours to weeks after injection and may include swallowing and breathing problems, loss of strength and muscle weakness all over the body, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, or loss of bladder control. Swallowing and breathing problems can be life threatening and there have been reports of death. You are at the highest risk if these problems are pre‐existing before injection. 

These effects could make it unsafe for you to drive a car, operate machinery, or do other dangerous activities. 

Do not have Dysport treatment if you: are allergic to Dysport or any of its ingredients (see the end of the Medication Guide for a list of ingredients), are allergic to cow's milk protein, had an allergic reaction to any other botulinum toxin product, such as Myobloc®, Botox®, or Xeomin®, have a skin infection at the planned injection site, under 18 years of age, or are pregnant or breastfeeding. 

The dose of Dysport is not the same as the dose of any other botulinum toxin product and cannot be compared to the dose of any other product you may have used. 

Tell your doctor about any swallowing or breathing difficulties and all your muscle or nerve conditions such as amyotrophic lateral sclerosis [ALS or Lou Gehrig's disease], myasthenia gravis, or Lambert‐Eaton syndrome, which may increase the risk of serious side effects including difficulty swallowing and difficulty breathing. Serious allergic reactions have occurred with the use of Dysport. Dry eye has also been reported. 

Tell your doctor about all of your medical conditions, including if you have surgical changes to your face, very weak muscles in the treatment area, any abnormal facial change, injection site inflammation, droopy eyelids or sagging eyelid folds, deep facial scars, thick oily skin, wrinkles that can't be smoothed by spreading them apart, or if you are pregnant or breastfeeding or planning to become pregnant or breastfeed. 

Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins and herbal and other natural products. Using Dysport with certain other medicines may cause serious side effects. Do not start any new medicines while taking Dysport without talking to your doctor first. 

Especially tell your doctor if you: have received any other botulinum toxin product, such as Myobloc® (rimabotulinumtoxinB), Botox® (onabotulinumtoxinA), or Xeomin® (incobotulinumtoxinA), in the last four months or any in the past (be sure your doctor knows exactly which product you received, have recently received an antibiotic by injection, take muscle relaxants, take an allergy or cold medicine, or take a sleep medicine. 

The most common side effects are nose and throat irritation, headache, injection site pain, injection site skin reaction, upper respiratory tract infection, eyelid swelling, eyelid drooping, sinus inflammation, and nausea. 

Ask your doctor if Dysport is right for you. 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‐800‐FDA‐1088. 

Please see Dysport Full Prescribing Information including Medication Guide at DysportUSA.com. 

The Restylane family of products are indicated for patients over the age of 21, and includes Restylane®, Restylane-L®, Restylane® Lyft with Lidocaine, Restylane® Silk, Restylane® Kysse, Restylane® Refyne, Restylane® Defyne, and Restylane® Contour. 

Restylane® and Restylane-L® are for mid-to-deep injection into the facial tissue for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds. Restylane® and Restylane-L® are also indicated for injection into the lips. 

Restylane® Lyft with Lidocaine is for deep implantation into the facial tissue for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds and for cheek augmentation and for the correction of age-related midface contour deficiencies. Restylane® Lyft with Lidocaine is also indicated for injection into the dorsal hand to correct volume loss. 

Restylane® Silk is for lip augmentation and for correction of perioral wrinkles. 

Restylane® Kysse is for lip augmentation and for correction of upper perioral wrinkles. 

Restylane® Refyne is for mid-to-deep injection into the facial tissue for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds. 

Restylane® Defyne is for mid-to-deep injection into the facial tissue for the correction of moderate to severe deep facial wrinkles and folds, such as nasolabial folds. Restylane® Defyne is also indicated for injection into the mid-to deep dermis (subcutaneous and/or supraperiosteal) for augmentation of the chin region to improve the chin profile in patients with mild to moderate chin retrusion. 

Restylane® Contour is for cheek augmentation and for the correction of midface contour deficiencies. 

Do not use if you have severe allergies with a history of severe reactions (anaphylaxis), are allergic to lidocaine or gram-positive bacterial proteins used to make hyaluronic acid, prone to bleeding, or have a bleeding disorder. The safety of use while pregnant or breastfeeding has not been studied. Tell your doctor if you have a history of scarring or pigmentation disorders as these side effects can occur with hyaluronic acid fillers. Tell your doctor if you are planning other cosmetic treatments (i.e., lasers and chemical peels) as there is a possible risk of inflammation at the injection site. 

Tell your doctor if you're taking medications that lower your body's immune response or affect bleeding, such as aspirin or warfarin, as these medications may increase the risk of bruising or bleeding at the gel injection site. Using these products on gel injection sites with skin sores, pimples, rashes, hives, cysts, or infections should be postponed until healing is complete. 

The most common side effects are swelling, redness, pain, bruising, headache, tenderness, lump formation, itching at the injection site, and impaired hand function. Serious but rare side effects include delayed onset infections, recurrence of herpetic eruptions, and superficial necrosis at the injection site. The risk of unintentional injection into a blood vessel is small but can occur and could result in serious complications, which may be permanent including, vision abnormalities, blindness, stroke, temporary scabs, or permanent scarring of the skin. As with all skin injection procedures, there is a risk of infection. 

To report a side effect with any Restylane® product, please call Galderma Laboratories, L.P. at 1-855-425-8722. 

To learn more about serious but rare side effects and full Important Safety Information, visit www.RestylaneUSA.com. 

Indication: Sculptra® (injectable poly-L-lactic acid) is indicated for use in people with healthy immune systems for the correction of shallow to deep nasolabial fold contour deficiencies and other facial wrinkles. 

Sculptra should not be used by people that are allergic to any ingredient of the product or have a history of keloid formation or hypertrophic scarring. Safety has not been established in patients who are pregnant, lactating, breastfeeding, or under 18 years of age. 

Sculptra has unique injection requirements and should only be used by a trained healthcare practitioner. Contour deficiencies should not be overcorrected because they are expected to gradually improve after treatment. 

Sculptra should not be injected into the blood vessels as it may cause vascular occlusion, infarction or embolic phenomena. Use at the site of skin sores, cysts, pimples, rashes, hives or infection should be postponed until healing is complete. Sculptra should not be injected into the red area (vermillion) of the lip or in the peri-orbital area.

The most common side effects after initial treatment include injection site swelling, tenderness, redness, pain, bruising, bleeding, itching and lumps. Other side effects may include small lumps under the skin that are sometimes noticeable when pressing on the treated area. Larger lumps, some with delayed onset with or without inflammation or skin discoloration, have also been reported

Sculptra is available only through a licensed practitioner. Complete Instructions for Use are available at www.SculptraUSA.com/IFU.

1. Data on file. MA-39680. Fort Worth, TX: Galderma Laboratories, L.P., 2019.
2. Sculptra. Instructions for Use. Galderma Laboratories, L.P., 2021.
3. Goldberg D, Guana A, Volk A, Daro-Kaftan E. Single-arm study for the characterization of human tissue response to injectable poly-L-lactic acid. Dermatol Surg. 2013;39(6):915-922.
4. Stein P, Vitavska O, Kind P, Hoppe W, Wieczorek H, Schürer NY. The biological basis for poly-L-lactic acid-induced augmentation. J Dermatol Sci. 2015;78:26-33.
5. Data on file. 43USSA1705ext clinical study report. Fort Worth, TX: Galderma Laboratories, L.P. 2021.

SOURCE Galderma